Less than 10% of people eligible to benefit from obesity jabs like Wegovy can access them, caution the global health agency as it releases its inaugural guidance on the drugs.
Considering in excess of 1,000,000,000 people worldwide currently living with obesity, it is calling for increased and just access to GLP-1 medication.
Per estimates, in excess of 2,000,000,000 will be obese by 2030 unless action is taken.
"Our latest guidance recognises that excess weight is a lifelong illness that can be treated with thorough and lifelong treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and supply-chain constraints are significant hurdles to broad access to the injections that can aid individuals in losing substantial body mass, explains the body.
Skinny Jab Supply Crisis
Even under the present most optimistic case, the supply of GLP-1 therapies might only reach approximately 100 million people – fewer than 10% of those who need them, according to the WHO.
The recommendation urges countries and companies to widen availability, via measures such as patent sharing.
A patent on a key compound – the core component of the drug Wegovy – is due to expire in a number of nations in 2026.
How Weight-Loss Drugs Function
GLP-1 drugs mimick a biological compound to reduce digestion speed, reduce hunger and enhance the sense of being full so people reduce food intake.
Patients usually begin shedding pounds after several weeks of commencing the once-weekly jabs.
Evidence suggests patients may put most of the weight back on after a year of halting the medication, as their usual food cravings resume.
To be carrying excess weight increases your likelihood for developing diseases, like type 2 diabetes, heart disease, brain attack, and some malignancies.
Excess weight concerns individuals in all nations and was linked to millions of fatalities worldwide in 2024, according to the health agency.
